[ad_1] Shares of Zee Entertainment Enterprises fell sharply Tuesday after news reports that Japan’s Sony Group may call off a merger of its India operations with the former. Zee Entertainment…
Tag: Ownership Changes
ByteDance in Talks With Potential Buyers to Sell Game Titles
[ad_1] TikTok’s parent company ByteDance is further scaling back its ambitions in the gaming industry and is in talks to sell game titles to several prospective buyers. Chinese media LatePost…
WSJ News Exclusive | Hewlett Packard Enterprise Near Deal to Buy Juniper Networks
[ad_1] Updated Jan. 8, 2024 6:31 pm ET Hewlett Packard Enterprise is in advanced talks to buy Juniper Networks for about $13 billion, in a bid to better position the…
JetBlue CEO to Step Down as Airline Awaits Judge’s Ruling on Spirit Airlines Merger
[ad_1] Robin Hayes will step down as CEO of JetBlue Airways next month after nearly nine years at the helm, citing a doctor’s advice, as the company waits to find…
Johnson & Johnson to Acquire Cancer-Treatment Developer Ambrx for $2 Billion
[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…
WSJ News Exclusive | Novartis in Advanced Talks to Buy Cytokinetics
[ad_1] Updated Jan. 8, 2024 1:14 pm ET Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as big pharmaceutical companies continue to snap up…
Boston Scientific To Acquire Axonics For About $3.7 Bln
[ad_1] Boston Scientific will acquire Axonics for about $3.7 billion in cash. The companies said on Monday that Axonics had agreed to be bought for $71 a share. Boston Scientific…
Merck to Buy Harpoon Therapeutics for $680 Million
[ad_1] Merck & Co.has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million. Merck on Monday said it will pay $23 a share in cash…
Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B
[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…